China The latest from Chinese pharma, with dealmaking continuing apace. Featured this week are Zai Lab’s latest IPO listing in Hong Kong, InventisBio Series D financing round for small-molecule drugs, as well as Bioduro and Sundio’s merger to create one of the largest CRDMOs with operations in China and the US.…
China Probably one of the most recognisable Chinese biotechs globally, Zai Lab may only be seven years old but the company has progressed rapidly in becoming a NASDAQ-listed company with not just one but two commercial assets through a stunningly effective strategy of forming productive collaborations with the most innovative biopharma…
China Samantha Du, Chairman and CEO of Zai Lab, the flagship China biotech company, shares her inspirational story of being one of the pioneers to forge a path for Chinese biopharma innovation; the recent product launch of Optune® in Hong Kong in December 2018, Zai Lab’s second product on the market;…
China Even though China’s pharmaceutical sector remains largely generics-based, the Middle Kingdom’s biotechnology scene has been flourishing in recent years. Now the world’s fastest-growing biopharmaceutical market, China can boast a much-improved context in terms of drug regulation, ease of doing business, research capabilities and access to capital. Below, we highlight 5…
See our Cookie Privacy Policy Here